The R package MAMS for designing multi-arm multi-stage clinical trials by Jaki, Thomas et al.
JSS Journal of Statistical Software
MMMMMM YYYY, Volume VV, Issue II. http://www.jstatsoft.org/
The R Package MAMS for Designing Multi-Arm
Multi-Stage Clinical Trials
Thomas Jaki
Lancaster University
Philip Pallmann
Lancaster University
Dominic Magirr
AstraZeneca
Abstract
In the early stages of drug development there is often uncertainty about the most
promising among a set of different treatments, different doses of the same treatment, or
combinations of treatments. Multi-arm multi-stage (MAMS) clinical studies provide an
efficient solution to determine which intervention is most promising. In this paper we dis-
cuss the R package MAMS that allows designing such studies within the group-sequential
framework. The package implements MAMS studies with normal, binary, ordinal, or time-
to-event endpoints in which either the single best treatment or all promising treatments
are continued at the interim analyses. Additionally unexpected design modifications can
be accounted for via the use of the conditional error approach. We provide illustrative
examples of the use of the package based on real trial designs.
Keywords: adaptive designs; conditional error; multi-arm, R, step-down procedure.
1. Introduction
Developing new medicines and health technologies is time-consuming and expensive. The
development of one novel treatment has been estimated to take 10–15 years and costs several
hundred million pounds on average (?). Because early-phase studies frequently evaluate
treatments on short-term endpoints, uncertainty often exists about which of a set of candidate
treatments should be selected for testing in a confirmatory phase III clinical trial. These
candidates can be truly different medications but can also be different doses of the same drug
or different combinations of multiple drugs. The high failure rate of phase III trials of around
50% (?) combined with their substantial cost (?) make selecting an appropriate treatment
for evaluation in phase III of paramount importance.
Seamless phase II/III multi-arm clinical trials that compare several active treatments with a
common control group are one potentially efficient solution to overcome this problem. These
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seamless studies use the initial part of the study (phase II) to learn about all treatments while
an in-depth evaluation occurs only on the promising one(s) in the second part (phase III). The
design typically applied for such an endeavour is called multi-arm multi-stage (MAMS). Using
data accumulated across both parts of the trial implies that decisions about the superiority
of (a) treatment(s) will be reached in a more efficient manner than with separate trials for
phases II and III. Incorporating a series of interim analyses to allow early stopping either for
efficacy or to drop ineffective treatments early has recently received attention (e.g., ?????).
While group-sequential designs found their way into standard software like R (?), Stata
(StataCorp, College Station, TX), and SAS (SAS Institute, Cary, NC) years ago and are
well established (?), programs for adaptive methods are still relatively rare. Here we give a
brief overview of available software implementations focusing on MAMS designs. Summaries
of software for adaptive designs more generally can be found in ? and the book chapters by
? and ?.
At present, there are three relevant R packages for adaptive trials on CRAN. adaptTest
(?) implements four different adaptive tests for two-arm two-stage designs. AGSDest (?)
computes estimates, p values, and lower one-sided confidence intervals for two-arm multi-stage
designs, using the conditional error principle to adjust for adaptations. The only package that
allows the design of multi-arm trials is asd (?). It provides a simulation function for multi-
arm two-stage designs with different selection rules at interim and uses p value combination
methods (inverse normal or Fisher’s combination test) for the outcome analysis (?). We are
not aware of any R package for adaptive trials with more than two arms and more than two
stages.
Stata modules for group-sequential designs are available (e.g., ?), but there are no routines
for more general adaptive methods, with the exception of nstage (?) and nstagebin (?)
that both implement MAMS designs. nstage has been available for several years (?) and
was recently updated (?). This module differs from the MAMS package described in this
paper in two principal ways. Firstly, the theory behind the MAMS package is based on
score statistics allowing continuous, binary, ordinal, and time-to-event data to be used as the
primary endpoints while nstage has been developed explicitly for time-to-event endpoints.
Secondly, the MAMS package focuses on designs that strictly control the FWER in the strong
sense. Similarly, nstagebin is only applicable to designs with binary outcomes, and its focus
is not on strong FWER control either.
SAS does not offer any functionality for adaptive methods other than group-sequential:
the only adaptation that can be made with the procedures SEQDESIGN and SEQTEST
is early stopping. Extensions by means of user-written programs are of course possible.
? provides a wealth of SAS macros for general adaptive designs. A SAS macro ADCCT
for two-stage designs with two or three active groups and mid-course treatment selection
(?) is available from https://cemsiis.meduniwien.ac.at/user/koenig-franz/research/
software/sas-macros-adcct.
Besides implementations of adaptive designs in commonly used statistical software, there are
also a few commercial standalone packages that cover certain types of confirmatory adaptive
methods, most notably East (Cytel, Cambridge, MA) and ADDPLAN (ICON, Dublin, Ireland).
The latter has an additional module MC with a wide range of functions for MAMS designs,
including sample size and power calculations, treatment selection at interim, sample size
reassessment, performance analyses (e.g., selection probabilities of specific treatment arms),
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closed testing, multiplicity-adjusted p values, and simultaneous confidence intervals.
In this manuscript we introduce the R package MAMS (?), which is an implementation of
the methods proposed in ?, ?, and ?. It facilitates the design of MAMS trials in which all
promising treatments are selected at a series of interim analyses. This has not been possible
so far in R for designs involving more than two arms and stages. Other convenient features
of MAMS are that unplanned design modifications are smoothly adjusted for, and it can use
a parameterisation of effect sizes that does not require any knowledge about the variability
in advance. A step-down variant where either the most promising treatment or all promising
treatments can be selected at interim is available, too.
In Section 2 we give an overview of the methodology described in ? and the ideas to allow for
unexpected design modifications (?). In Section 3 we highlight a few computational aspects
of the package. Section 4 provides examples of the use of the package based on real trials
focusing on the interpretation of the results before we conclude with a discussion in Section
5.
2. The underlying methodology
We consider the situation where K treatments are compared to a common control group
(indexed by zero). Of interest is to test if treatment k is superior to control, which formally
corresponds to
H01 : µ1 ≤ µ0, . . . , H0K : µK ≤ µ0 ,
where µk is the mean response of a patient on treatment k = 0, 1, . . . ,K. Observations of the
primary endpoint are modelled as normally distributed random variables with equal known
variance, σ2, but potentially different mean levels, µ0, . . . , µK . At up to J time points the
data accumulated so far will be analysed and each treatment arm either continued or stopped.
If all experimental arms are stopped, the trial terminates. We denote the number of subjects
on control during the first stage by n and the number of observations on arm k up to stage j
by r
(j)
k n. Often equal numbers of observations on each experimental treatment are assumed
so that r
(j)
1 = . . . = r
(j)
K = r
(j). To allocate an equal number of subjects to each treatment
and each stage, r(j) = r
(j)
0 = jr
(1), for example.
2.1. Designing the study
To decide which treatments are continued and which are stopped at each analysis time point,
comparative Z statistics are defined as
Z
(j)
k =
µˆ
(j)
k − µˆ(j)0
σ
√
r
(j)
k
+r
(j)
0
r
(j)
k
r
(j)
0 n
, k = 1, . . .K ; j = 1, . . . , J ,
where µˆk is the mean measurement on treatment k = 0, . . . ,K and σ denotes the known
standard deviation. At stage j recruitment to treatment k is stopped for futility if Z
(j)
k
≤ lj , i.e., the corresponding test statistics is below a pre-defined lower boundary value lj .
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Similarly we can reject the null hypothesis of non-superiority of treatment k over control if
the corresponding test statistic exceeds an upper boundary, Z
(j)
k > uj . In the event that one
or more treatments are shown to be superior to control, the trial stops. If lj < Z
(j)
k ≤ uj
further patients are recruited to each remaining treatment k and control. We set the final
boundary value lJ = uJ to enforce a decision about every superiority hypothesis at the end
of the trial.
To determine the boundaries (lj , uj), j = 1, . . . , J we require that the familywise error rate
(FWER), defined as
P (reject at least one true H0k, k = 1, . . . ,K),
be controlled at a pre-specified level α. This probability can analytically be found as a J
dimensional integral that depends on the boundaries, l1, . . . lJ−1, u1, . . . , uJ and how subjects
are allocated to the arms and stages. The latter is usually pre-specified, leaving 2 × J − 1
unknowns when finding the FWER of a design. To determine the boundary values to ensure
FWER control different approaches can be taken. The first is to determine the boundaries
to satisfy some optimality criterion subject to controlling the FWER as described in ?. The
second approach is to utilise an error-spending approach as described in ?. The third approach
pre-specifies functions that relate the boundaries to the final critical value, lj = g(uJ), uj =
f(uJ) j = 1, . . . , J − 1, leaving one equation and one unknown. The third option is explicitly
implemented in the MAMS package while it can be used as the basis for the other two ideas
as well; this would require the user to write a suitable optimisation routine.
To obtain the required sample size, the least favourable configuration (LFC, ?) can be utilised.
The power under the LFC is, without loss of generality, defined as the probability to reject
H01 given µ1 − µ0 = δ and µk − µ0 = δ0 for k = 2, . . . ,K where δ is an effect that, if present,
we would like to detect with high probability and δ0 is an effect that, if present, would not
be of interest.
In addition to the standard parameterisation of the effect sizes in terms of δ and δ0, the
MAMS package implements a slightly non-standard parameterisation as probabilities. The
interesting treatment effect, p, that if present we would like to find with high probability
and an uninteresting effect, p0 are both parameterised as P (Xk > X0) where Xi denotes
the random response on treatment i, i.e., the probability of a randomly selected person on
treatment k observing a better outcome than a random person on control. As a consequence
p = 0.5 implies that both the experimental treatment and control perform equally well. We
utilise this parameterisation as no knowledge about the variance, σ2, is required. To obtain
p from the traditional effect size, δ, one can simply use p = Φ
(
δ√
2σ2
)
.
2.2. Dealing with unexpected design modifications
In the previous section we have outlined how a MAMS design can be determined. Unfortu-
nately, certain aspects of the design are often quite difficult to specify a-priori, and it is well
known that deviations from the planned design, such as changing the sample size or dropping
treatment arms, can compromise the operating characteristics of the design, and in particular
FWER and power, dramatically. It is therefore useful to be able to adjust the design to
account for such unexpected deviations. Here we will outline the underlying methodology to
do so, which is described comprehensively for MAMS designs in ?.
Journal of Statistical Software 5
The first ingredient to allow design modifications is the conditional error principle (?). It
utilises the conditional probability of rejecting H0k under the null hypothesis given a design
and the data observed so far, called the conditional error. The conditional error principle
then states that a new design controls the FWER if the conditional error of this design does
not exceed the conditional error of the original design. As a consequence the conditional
error approach can be used to adjust for design modifications within each of the pairwise
comparisons contrasting one experimental arm against control.
Secondly, to ensure FWER control over all comparisons, the closure principle (?) can be
utilised. In order to apply the closure principle to the family of null hypotheses, H1, . . . ,HK
(omitting the index 0 for brevity), local hypothesis tests for all intersection hypotheses, HI =
∩Kk=1HK , are found. The elementary hypothesis Hk can then be rejected at level α if and
only if all HI containing Hk can be rejected at level α.
3. Computational aspects of the MAMS package
After a brief description of the underlying methodology we will now highlight some of the
computational aspects that have been used in the implementation of the MAMS package. The
first notable aspect is the computation of the FWER and power, which do not have a closed-
form solution. Instead an integral of dimension J (the number of stages) over multivariate
normal distributions needs to be evaluated. The multivariate normal densities are evaluated
using the package mvtnorm (?), which utilises the algorithms of ?. The outer integrals are
solved using quadrature and the midpoint rule. The number of points used for the quadrature
can be controlled with the argument N, but the default will hardly ever have to be changed
by the user. The computational complexity in solving the FWER and power constraint
lies in the number of stages rather than the number of treatment arms. Consequently, the
implementation used in the package is efficient for any number of treatment arms provided
that the number of stages is small. For designs with more than two stages, however, computing
a design might take several minutes.
When computing the power of the design we use a “divide and conquer” strategy. In order to
determine the power it is necessary to find the probability of stopping which, by construction,
could happen at any stage. To simplify the computation, it is helpful to observe that it
is still only possible to stop at exactly one of the stages. As a consequence it is possible
to find the probability of stopping at each stage separately and simply sum over all these
probabilities in order to find the overall power. To determine the sample size required to
achieve a pre-specified power a simple loop is used. To potentially speed computation up
further it is possible to set the starting value of the loop via nstart. This is particularly
helpful as it is well known that the maximum sample size of a design with interim analyses
will not typically be smaller than the equivalent fixed-sample design for continuous endpoints.
In a similar manner, the loop is terminated at a maximum value for the sample size, which
is by default 3 times the sample size of the equivalent fixed-sample design with all other
parameters unchanged, but this can be overridden by specifying a value for nstop.
4. Applications
In this section we showcase some uses of the MAMS package and how to interpret the cor-
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responding R output. The TAILoR study (?) serves as the motivating example, and so we
consider a design that evaluates three different experimental treatment arms against control,
using a one-sided type I error rate of 5% and 90% power. The interesting effect size is set
to p = 0.65, which corresponds to an effect of δ = 0.545σ on the traditional scale. The
uninteresting treatment effect is chosen as p0 = 0.55 (δ0 = 0.178σ). MAMS allows the user
to choose whichever parameterisation they prefer for specifying the effect sizes.
4.1. A single-stage design
Designing studies including finding the boundaries of the design and the required sample
size can be achieved with the function mams. The parameters of the function correspond to
the definition in Section 2 so that K, e.g., specifies the number of experimental treatments
that are to be compared to control, and J the number of stages. We begin by considering a
single-stage design (J=1), which corresponds to a design based on a standard Dunnett test
(?) involving K=3 experimental treatments. We use equal allocation between treatment arms,
which is specified via r=1 for the experimental arms and r0=1 for control.
R> library("MAMS")
R> m1 <- mams(K=3, J=1, p=0.65, p0=0.55, r=1, r0=1, alpha=0.05, power=0.9)
An overview of the design is displayed with print(m1) or summary(m1) or simply m1.
R> m1
Design parameters for a 1 stage trial with 3 treatments
Stage 1
Cumulative sample size per stage (control): 79
Cumulative sample size per stage (active): 79
Maximum total sample size: 316
Stage 1
Upper bound: 2.062
Lower bound: 2.062
The output produced specifies the number of patients required on control and each treatment
arm as well as the boundaries of the design. A total of 316 patients, 79 on control and 79 on
each of the 3 experimental treatments, are required for this study. The null hypothesis for
treatment k can be rejected if the corresponding test statistic is larger than 2.062.
The same design can also be specified on the scale of traditional effect sizes rather than
probabilities, by setting p and p0 to NULL and specifying values for delta, delta0, and sd.
The output will be exactly the same as for m1.
R> m1d <- mams(K=3, J=1, p=NULL, p0=NULL, delta=0.545, delta0=0.178, sd=1,
+ r=1, r0=1, alpha=0.05, power=0.9)
In the remainder of this section we will specify all effect sizes on the probability scale, but
converting them is straightforward in R:
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R> pnorm(0.545/sqrt(2))
[1] 0.6500195
R> qnorm(0.65) * sqrt(2)
[1] 0.5449254
4.2. Multi-stage designs with different boundary shapes
Since only a single stage was used in this initial example, no form of the boundaries had
to be specified. For multi-stage designs the shape of the lower and upper boundary can be
defined via the arguments lshape and ushape. These arguments can either invoke the pre-
defined shapes following ?, ? or the triangular test (?) using options "pocock", "obf", or
"triangular", respectively. Alternatively a constant value (option "fixed") can be specified.
Finally, custom boundaries can be defined as a function that requires exactly one argument
for the number of stages and returns a vector of the same length. The lower boundary shape
must be non-decreasing while the upper boundary shape must be non-increasing to ensure
reasonable trial designs are found.
In the following example we calculate a two-stage design investigating three experimental
treatments. Triangular boundaries are used with a cumulative sample size ratio of r=1:2
between first and second stage, i.e., the interim analysis is scheduled after half of the maximum
number of patients have been recruited and their outcome observed, and twice as many
subjects on control as on the experimental arms, as specified by r0=c(2, 4).
R> m2 <- mams(K=3, J=2, p=0.65, p0=0.55, r=1:2, r0=c(2, 4), alpha=0.05,
+ power=0.9, ushape="triangular", lshape="triangular")
R> m2
Design parameters for a 2 stage trial with 3 treatments
Stage 1 Stage 2
Cumulative sample size per stage (control): 76 152
Cumulative sample size per stage (active): 38 76
Maximum total sample size: 380
Stage 1 Stage 2
Upper bound: 2.359 2.225
Lower bound: 0.786 2.225
The cumulative sample sizes at stages 1 and 2 are given in tabular form in the R output.
The trial may be stopped after the first analysis, either for futility (if all the Z statistics are
less than 0.786) or superiority (if at least one Z statistic exceeds 2.359). In all other cases
the trial is to be taken to the second stage where additional patients are randomised to any
experimental treatment whose Z statistic falls between the boundary values of the first stage
and control. A critical value of 2.225 is used at the second analysis to decide whether a
treatment shall be deemed superior to control or not.
Our next example involves three treatment arms in a three-stage design with equal numbers of
subjects added at every stage as well as balance of sample size between control and treatment
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groups; this requires us to specify the cumulative sample sizes as r=1:3 and r0=1:3. To
illustrate the versatility of the function mams, we do not use any of the pre-defined boundary
shapes. Instead we implement a fixed lower bound of zero (with lshape="fixed" and lfix=0)
and an upper boundary where the first-stage critical value is three times as large as the final
critical value. To achieve this, ushape is specified as a function that returns the vector (3, 2,
1) (return(x:1)).
R> m3 <- mams(K=3, J=3, p=0.65, p0=0.55, alpha=0.05, power=0.9, r=1:3, r0=1:3,
+ ushape=function(x) return(x:1), lshape="fixed", lfix=0)
R> m3
Design parameters for a 3 stage trial with 3 treatments
Stage 1 Stage 2 Stage 3
Cumulative sample size per stage (control): 27 54 81
Cumulative sample size per stage (active): 27 54 81
Maximum total sample size: 324
Stage 1 Stage 2 Stage 3
Upper bound: 6.125 4.083 2.042
Lower bound: 0.000 0.000 2.042
The maximum total sample size is considerably lower than with design m2 (324 versus 380),
and so is the critical value at the final stage (2.042 versus 2.225). These feigned advantages
come, however, at the cost of very large upper boundary values at stages 1 and 2 (6.125 and
4.083) that make it extremely hard to stop the trial early, so this is unlikely to be a useful
design in practice. On a related note, if a design should not allow stopping for one of efficacy
or futility at all, we can achieve this by setting lfix=-Inf or ufix=Inf, respectively.
We compare the boundaries of our “own” design m3 with those of the corresponding standard
designs (Pocock, O’Brien-Fleming, triangular) graphically using the plot function that comes
with the MAMS package. First we have to compute the boundaries of the standard designs
for J=3 stages and sample size allocations as in m3. Notice that the computation of designs
with more than 2 stages can take several minutes.
R> poc <- mams(K=3, J=3, p=0.65, p0=0.55, r=1:3, r0=1:3, alpha=0.05, power=0.9,
+ ushape="pocock", lshape="pocock")
R> obf <- mams(K=3, J=3, p=0.65, p0=0.55, r=1:3, r0=1:3, alpha=0.05, power=0.9,
+ ushape="obf", lshape="obf")
R> tri <- mams(K=3, J=3, p=0.65, p0=0.55, r=1:3, r0=1:3, alpha=0.05, power=0.9,
+ ushape="triangular", lshape="triangular")
Then we plot the boundaries with identical scaling of the vertical axes (using the argument
ylim) to make the graphs visually comparable:
R> par(mfrow=c(2, 2))
R> plot(poc, ylim=c(-5, 7), main="Pocock")
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R> plot(obf, ylim=c(-5, 7), main="O'Brien-Fleming")
R> plot(tri, ylim=c(-5, 7), main="Triangular")
R> plot(m3, ylim=c(-5, 7), main="Self-designed")
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Figure 1: Stopping boundaries for a three-arm three-stage design using the methods of Pocock
(top left), O’Brien-Fleming (top right), the triangular test (bottom left), and our own design
with a fixed lower bound of zero and an upper bound whose first-stage critical value is three
times as large as the final one (bottom right).
Figure 1 displays the shapes of all four designs. We see that the triangular design has
clearly the narrowest boundaries (and therefore the highest chances of stopping the trial
early) whereas the self-designed variant leads to extraordinarily high upper boundary values
at the first two interim analyses.
4.3. Evaluating the properties of a design
To evaluate the properties of a particular design via simulation, the function mams.sim can
be employed. It allows for flexible numbers of subjects per arm and stage in the form of a
J × (K + 1) matrix nMat. In addition to the upper and lower boundaries (u and l), a vector
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of true success probabilities (pv) is required (or alternatively a vector of true effect sizes
(deltav) and a standard deviation (sd)). The parameter ptest allows to specify rejection of
which hypotheses should be counted in the power calculation. We evaluate the properties of
the two-stage design m2 under the global null hypothesis (i.e., a true effect size of p = 0.5 or
δ = 0 for all treatments) with 100,000 simulation runs.
R> m2sim <- mams.sim(nsim=1e5, nMat=t(m2$n * m2$rMat), u=m2$u, l=m2$l,
+ pv=rep(0.5, 3), ptest=1:2)
R> m2sim
Simulated error rates based on 1e+05 simulations
Prop. rejecting at least 1 hypothesis: 0.049
Prop. rejecting first hypothesis (Z_1>Z_2,...,Z_K) 0.017
Prop. rejecting hypotheses 1 or 2: 0.034
Expected sample size: 244.578
The probability of rejecting at least one hypothesis is 0.049, and since we simulated under
the global H0, this corresponds to a FWER of 5% as desired. The power to reject the first
hypothesis when it has the largest estimated effect is 0.017, and the power to reject either H1
or H2 or both of them (as specified by ptest=1:2) is 0.034. The expected number of patients
required for the trial under the global H0 is 244.6 in contrast to the maximum required of
380.
The function mams.sim is also useful to simulate and compare expected sample sizes of dif-
ferent designs. We illustrate this for the designs poc, obf and tri (whose boundaries are
shown in Figure 1) under the LFC of the alternative, i.e., one treatment’s effect size equals
p = 0.65 whereas the effect sizes for all other treatments are equal to p0 = 0.55, using 100,000
simulation runs.
R> pocsim <- mams.sim(nsim=1e5, nMat=t(poc$n * poc$rMat), u=poc$u, l=poc$l,
+ pv=c(0.65, rep(0.55, 2)), ptest=1)
R> obfsim <- mams.sim(nsim=1e5, nMat=t(obf$n * obf$rMat), u=obf$u, l=obf$l,
+ pv=c(0.65, rep(0.55, 2)), ptest=1)
R> trisim <- mams.sim(nsim=1e5, nMat=t(tri$n * tri$rMat), u=tri$u, l=tri$l,
+ pv=c(0.65, rep(0.55, 2)), ptest=1)
Similarly, we can obtain the design properties under the global null hypothesis by setting
pv=rep(0.5, 3). Table 1 summarises minimum, maximum, and expected sample sizes of the
three designs. We see that under both the LFC and the global H0 the triangular design is
expected to require the lowest number of patients. On the other hand, O’Brien-Fleming has
the lowest minimum and maximum but the highest expected sample size under the LFC of
all three designs. Under the global H0 both the Pocock and O’Brien-Fleming designs have
expected sample sizes that are very close to their respective maxima.
4.4. A step-down design
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Design Minimum Maximum Expected (LFC) Expected (H0)
Pocock 165 396 232.4 385.6
O’Brien-Fleming 140 336 259.2 334.0
Triangular 170 408 217.3 222.3
Table 1: Minimum, maximum, and (simulated) expected sample sizes of three-stage designs
involving three experimental treatment arms with Pocock, O’Brien-Fleming, and triangular
boundaries under the least favourable configuration of the alternative (LFC) and the global
null hypothesis (H0).
A direct improvement over the basic design can be achieved by using a step-down version of the
test. The function stepdown.mams implements such a design that selects at interim either all
promising treatments (selection="all.promising") or only the best performing treatment
(selection="select.best") from those whose test statistics are between the upper and
lower boundaries (?). If the trial is stopped early, making a selection becomes obsolete, but
note that we consider stopping boundaries as non-binding. The step-down procedure makes
use of closed testing, as described in Section 2.2 and ?.
We reuse the three-arm two-stage design m2 with 76 and 38 observations in stage 1 and cumu-
lative sample sizes at stage two of 152 and 76 on control and active treatments, respectively.
The sample size of the study can be specified through the matrix nMat that has J rows and
K columns where the first column contains the values for the control group. A lower bound-
ary can be set via lb, and we set it to 0.786 as in the original design. We can then choose
how much of the total familywise error we want to spend at each stage using the argument
alpha.star, and we choose to spend, in line with the triangular test, α∗1 = 0.026 at the first
interim analysis, with the remaining α level being used at the second analysis. We compare
the selection rules all.promising and select.best:
R> m2.all <- stepdown.mams(nMat=matrix(c(76, 152, rep(c(38, 76), 3)),
+ nrow=2, ncol=4), lb=m2$l[1], alpha.star=c(0.026, 0.05),
+ selection="all.promising")
R> m2.best <- stepdown.mams(nMat=matrix(c(76, 152, rep(c(38, 76), 3)),
+ nrow=2, ncol=4), lb=m2$l[1], alpha.star=c(0.026, 0.05),
+ selection="select.best")
The output for all intersections and stages is verbose, therefore we summarise only the upper
boundary values in Table 2 with the full output provided in Appendix A. One can see that
the option to proceed with more than one promising treatment comes at the cost of higher
stopping boundaries for the intersection hypotheses at stage 2. So in order to reject the global
null hypothesis at the second stage, a test statistic needs to exceed 2.22 while it only needs
to be larger than 2.17 if only the best arm is chosen at the interim analysis. The boundaries
are the same for the elementary hypotheses H1, H2, and H3 as well as for the intersection
hypotheses H12, H13, and H23 because the sample sizes were chosen to be equal in all active
treatment arms. A graphical display of the stopping boundaries using the plot function is
shown in Figure 2.
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R> par(mfrow=c(1, 2))
R> plot(m2.all, main="Select all promising", col=c(1, 1, 2, 1, 2, 2, 4))
R> plot(m2.best, main="Select the best", col=c(1, 1, 2, 1, 2, 2, 4))
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Figure 2: Stopping boundaries for a three-arm two-stage step-down design with selection of
all promising treatments at interim (left) or just the single best treatment (right).
Hypotheses Stage 1 Stage 2 (best) Stage 2 (all)
H1, H2, H3 1.94 1.71 1.72
H12, H13, H23 2.21 2.02 2.06
H123 2.36 2.17 2.22
Table 2: Upper boundaries for the elementary (H1, H2, H3), intersection (H12, H13, H23),
and global (H123) hypotheses of a three-arm two-stage step-down design involving selection
of either the single best or all promising treatments at interim.
4.5. Dealing with unforeseen design modifications
Two other functions of the package, new.bounds and stepdown.update, allow for unexpected
design modifications to be taken into account. The function new.bounds recalculates the
boundary values when the sample sizes achieved are not as planned in advance. We consider
again the two-stage design m2 where 76 patients were required per stage in the control arm
and 38 patients per stage for each of the three experimental treatment arms. Now assume
these requirements could not be met and the observed sample sizes at the interim analysis
were 75 for control and 40, 35, and 41 for the experimental treatments. We can recalculate
the final boundary value with new.bounds in which we specify the interim bounds u=2.359
and l=0.786 (as obtained for m2). The sample sizes as observed at stage 1 and planned for
stage 2 are given in the J × (K + 1) matrix nMat.
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R> m2.nb <- new.bounds(K=3, J=2, nMat=matrix(c(75, 152, 40, 76, 35, 76, 41, 76),
+ nrow=2, ncol=4), alpha=0.05, u=m2$u[1], l=m2$l[1], ushape="triangular",
+ lshape="triangular")
R> m2.nb
Design parameters for a 2 stage trial with 3 treatments
Stage 1 Stage 2
Upper bound: 2.359 2.224
Lower bound: 0.786 2.224
We find that as a result of the deviation from the planned sample size at the interim analysis,
the final boundary value has been lowered from 2.225 in the original m2 design to 2.224.
The function stepdown.update uses the conditional error approach to incorporate unplanned
sample size reassessment and/or treatment selection (e.g., elimination of treatment arms
due to safety issues) while maintaining control of the desired FWER. We once again base
this example on the original three-arm two-stage design but consider the step-down version
(m2.all) and assume there were some unforeseen design changes during the course of the
trial. Initially the sample sizes at interim were planned to be 76 for the control group and 38
per active treatment arm. At the interim analysis, we now wish to take into account three
deviations from the planned study. Firstly, we want to account for the deviation from the
desired sample size which, as in the previous example, turned out to be 75 for control and
40, 35, and 41 for the experimental treatments, which translates to nobs=c(75, 40, 35,
41) in the function stepdown.update. Secondly, treatment 2 has been dropped from the
study due to safety, so that only treatment arms 1 and 3 (selected.trts=c(1, 3)) are to
be continued. Finally, following a reassessment of the sample size, we wish to increase the
cumulative sample size at the second stage by 50% from 152 to 228 in the control arm and
76 to 114 in the active arms. We can specify this using nfuture=matrix(c(228, 114, 35,
114), 1, 4). Notice that since treatment arm 2 has already been abandoned, no additional
patients are recruited beyond the 35 already in the study. Further supposing the interim
evaluation yielded Z statistics of zscores=c(1.1, 0.9, 0.9), we can calculate the modified
design.
R> m2.update <- stepdown.update(current.mams=m2.all, nobs=c(75, 40, 35, 41),
+ zscores=c(1.1, 0.9, 0.9), selected.trts=c(1, 3),
+ nfuture=matrix(c(228, 114, 35, 114), nrow=1, ncol=4))
The complete output of m2.update is provided in Appendix B and we summarise it in Table
3 (column “Updated”). The boundaries for the elementary hypothesis H1 and H3 have been
slightly increased to account for the change in sample size while the boundary for H2 has been
slightly decreased. Similarly, the boundary for the intersection hypothesis involving only the
remaining treatments (H13) has been increased while the others have been decreased. No
change in the threshold for the global null hypothesis (H123) is observed in this example. As
before we can also illustrate the updated design using the plot function.
4.6. Non-normal endpoints
Up to this point we have focused on normally distributed endpoints. Based on asymptotic
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Hypothesis Initial Updated (cond. error)
H1 1.72 1.73 (0.088)
H2 1.72 1.71 (0.069)
H3 1.72 1.79 (0.058)
H12 2.06 1.92 (0.056)
H13 2.06 2.14 (0.051)
H23 2.06 1.90 (0.043)
H123 2.22 2.22 (0.041)
Table 3: Initial and updated upper boundaries (with conditional errors) for the elementary
(H1, H2, H3), intersection (H12, H13, H23), and global (H123) hypotheses of a three-arm two-
stage step-down design involving selection of all promising treatments at interim. Treatment
2 has been dropped at the interim analysis and the sample size for the remaining comparisons
increased.
theory, MAMS can also handle non-normal endpoints by exploiting the asymptotic properties
of efficient score statistics (?), as we will demonstrate for ordinal, binary, and time-to-event
outcome data.
Ordinal and binary endpoints
Ordinal data consist of multiple different categories that have a natural order, which is com-
mon for quality-of-life scores, pain scores, and similar questionnaire-based outcomes. Our
illustration here is motivated by the ASCLEPIOS study (?) and its example analyses in ?
and ?.
We design a MAMS trial with three experimental treatments and a control arm, one interim
analysis after half the patients have provided an outcome measure, and triangular boundaries
in a setting with an ordinal primary endpoint, under the assumption of proportional odds.
We expect that under control conditions the probabilities of falling into each of six categories,
ordered from best to worst, are 0.075, 0.182, 0.319, 0.243, 0.015, and 0.166. Suppose the
interesting effect is a doubling in the probability of falling into one of the two best categories
combined, from 25.7 to 51.4%, for any experimental arm. This corresponds to an odds ratio
(OR) of 3.06 and a log-OR of 1.12. The uninteresting effect shall be one quarter of the
interesting effect on the log-OR scale i.e., a log-OR of 0.28 or an OR of 1.32.
To find the boundary values and sample sizes, we can use the function ordinal.mams, which
is a wrapper for mams with additional inputs prob for the probabilities of falling into each cat-
egory (which must sum up to one), as well as or and or0 for the interesting and uninteresting
treatment effects, respectively, on the OR scale:
R> prob <- c(0.075, 0.182, 0.319, 0.243, 0.015, 0.166)
R> mord <- ordinal.mams(prob=prob, or=3.06, or0=1.32, K=3, J=2, alpha=0.05,
+ power=0.9, r=1:2, r0=1:2, ushape="triangular", lshape="triangular")
R> mord
Design parameters for a 2 stage trial with 3 treatments
Stage 1 Stage 2
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Cumulative sample size per stage (control): 34 68
Cumulative sample size per stage (active): 34 68
Maximum total sample size: 272
Stage 1 Stage 2
Upper bound: 2.330 2.197
Lower bound: 0.777 2.197
The function ordinal.mams can also be used for binary endpoints as they are a simple special
case of ordinal data where prob has only two categories (success/failure, yes/no, etc.) and
the proportional odds assumption becomes obsolete.
Time-to-event endpoints
Another useful extension of MAMS is to event-time outcomes e.g., when the primary endpoint
is survival. In that case the effect sizes δ and δ0 must be specified in terms of log-hazard
ratios (log-HRs), which are assumed to be asymptotically normal, and the standard deviation
is σ = 1. Sample sizes are expressed in terms of events (e.g., deaths), e, rather than numbers
of patients, n. As a consequence, we set r
(1)
k = 1 and r
(j)
k = e
(j)
0 /e
(1)
0 . The underlying
approximation should work well if the effect size is small, the number of allocated patients
patients per arm is equal at each stage, and there are few ties in relation to the number of
different event times.
Assume we want to design a MAMS trial with three experimental treatment arms and a
control, using triangular boundaries. One interim analysis is to be conducted upon observing
e
(1)
0 events in the control arm, set to half of the total number of events in that arm. Our
interesting effect size is a HR of 1.5, corresponding to a log-HR of 0.405, and the uninteresting
effect size is a HR of 1.1 i.e., a log-HR of 0.095.
We can calculate the boundary values and sample sizes with the function tite.mams, which
is another wrapper for mams with additional inputs hr and hr0 for the interesting and unin-
teresting treatment effects, respectively, on the HR scale:
R> mtite <- tite.mams(hr=1.5, hr0=1.1, K=3, J=2, alpha=0.05, power=0.9,
+ r=1:2, r0=1:2, ushape="triangular", lshape="triangular")
R> mtite
Design parameters for a 2 stage trial with 3 treatments
Stage 1 Stage 2
Cumulative number of events per stage (control): 81 162
Cumulative number of events per stage (active): 81 162
Maximum total number of events: 648
Stage 1 Stage 2
Upper bound: 2.330 2.197
Lower bound: 0.777 2.197
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The sample size output here is given as the required number of events, which is obviously
smaller than the required number of patients. We refer to ? for guidance how to estimate the
maximum total number of patients to be recruited.
5. Discussion
In this paper we have described the R package MAMS for designing multi-arm multi-stage
clinical trials, as well as some of the underlying statistical methodology. We have shown how to
design a study with the package’s basic function mams or its step-down variant stepdown.mams,
how to evaluate properties like the expected sample size and power of a design with mams.sim,
how to incorporate unforeseen changes using new.bounds and stepdown.update, and how
to use the functionality of MAMS for ordinal, binary, and time-to-event endpoints with
ordinal.mams and tite.mams. In addition to studying the numerical R output, it is of-
ten instructive to assess and compare designs using graphics, which can be accomplished with
the package’s automated plot function for the boundaries.
All this provides a convenient toolkit for planning and adapting efficient and highly flexible
trials: inclusion of multiple experimental treatment arms increases the chances of a success;
interim analyses allow to eliminate futile treatments early on and to stop the trial as soon
as efficacy of any treatment is established; spontaneous design modifications (e.g., due to a
safety issue) or sample size reassessment are smoothly taken into account using the conditional
error principle. The theoretical foundations have been around for a few years (??), but they
will only make a real impact on how clinical trials are conducted if user-friendly software is
available and accessible. Given the limited range of adaptive design software that has been
published to date, we consider MAMS a big step forward. It is the first package in R for
adaptive trials with more than one active treatment group and at the same time more than
one interim analysis for various types of endpoints.
The functionality of MAMS is extendable beyond pre-defined methods; for example, the
design functions allow the user to implement arbitrarily shaped boundaries, with the only
restrictions that the lower boundary be non-decreasing and the upper one non-increasing. In
practice, however, it is often advisable to apply established methods whose properties are well
understood. Especially the triangular test of ? is an appealing candidate: although it may
raise the maximum sample size in comparison to, e.g., the O’Brien-Fleming design, it usually
has a substantially lower expected sample size compared to other designs (?).
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A. A step-down test
R> m2.all
Design parameters for a 2 stage trial with 3 treatments
Stage 1 Stage 2
Cumulative sample size (control): 76 152
Cumulative sample size per stage (treatment 1 ): 38 76
Cumulative sample size per stage (treatment 2 ): 38 76
Cumulative sample size per stage (treatment 3 ): 38 76
Maximum total sample size: 380
Intersection hypothesis H_{ 1 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
Upper boundary 1.9400000 1.72
Lower boundary 0.7864987 1.72
Intersection hypothesis H_{ 2 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
Upper boundary 1.9400000 1.72
Lower boundary 0.7864987 1.72
Intersection hypothesis H_{ 1 2 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
Upper boundary 2.2100000 2.06
Lower boundary 0.7864987 2.06
Intersection hypothesis H_{ 3 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
Upper boundary 1.9400000 1.72
Lower boundary 0.7864987 1.72
Intersection hypothesis H_{ 1 3 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
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Upper boundary 2.2100000 2.06
Lower boundary 0.7864987 2.06
Intersection hypothesis H_{ 2 3 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
Upper boundary 2.2100000 2.06
Lower boundary 0.7864987 2.06
Intersection hypothesis H_{ 1 2 3 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
Upper boundary 2.3600000 2.22
Lower boundary 0.7864987 2.22
R> m2.best
Design parameters for a 2 stage trial with 3 treatments
Stage 1 Stage 2
Cumulative sample size (control): 76 152
Cumulative sample size per stage (treatment 1 ): 38 76
Cumulative sample size per stage (treatment 2 ): 38 76
Cumulative sample size per stage (treatment 3 ): 38 76
Maximum total sample size: 380
Intersection hypothesis H_{ 1 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
Upper boundary 1.9400000 1.71
Lower boundary 0.7864987 1.71
Intersection hypothesis H_{ 2 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
Upper boundary 1.9400000 1.71
Lower boundary 0.7864987 1.71
Intersection hypothesis H_{ 1 2 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
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Upper boundary 2.2100000 2.02
Lower boundary 0.7864987 2.02
Intersection hypothesis H_{ 3 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
Upper boundary 1.9400000 1.71
Lower boundary 0.7864987 1.71
Intersection hypothesis H_{ 1 3 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
Upper boundary 2.2100000 2.02
Lower boundary 0.7864987 2.02
Intersection hypothesis H_{ 2 3 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
Upper boundary 2.2100000 2.02
Lower boundary 0.7864987 2.02
Intersection hypothesis H_{ 1 2 3 }:
Stage 1 Stage 2
Conditional error 0.0260000 0.05
Upper boundary 2.3600000 2.17
Lower boundary 0.7864987 2.17
B. A design with unexpected modifications
R> m2.update
Design parameters for a 2 stage trial with 3 treatments
Stage 1 Stage 2
Cumulative sample size (control): 75 228
Cumulative sample size per stage (treatment 1 ): 40 114
Cumulative sample size per stage (treatment 2 ): 35 35
Cumulative sample size per stage (treatment 3 ): 41 114
Maximum total sample size: 491
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Intersection hypothesis H_{ 1 }:
Stage 1 Stage 2
Conditional error 0.0000000 0.08843773
Upper boundary 1.9400000 1.73000000
Lower boundary 0.7864987 1.73000000
Intersection hypothesis H_{ 2 }:
Stage 1 Stage 2
Conditional error 0.0000000 0.06896401
Upper boundary 1.9400000 1.71000000
Lower boundary 0.7864987 1.71000000
Intersection hypothesis H_{ 1 2 }:
Stage 1 Stage 2
Conditional error 0.0000000 0.05613374
Upper boundary 2.2100000 1.92000000
Lower boundary 0.7864987 1.92000000
Intersection hypothesis H_{ 3 }:
Stage 1 Stage 2
Conditional error 0.0000000 0.0576666
Upper boundary 1.9400000 1.7900000
Lower boundary 0.7864987 1.7900000
Intersection hypothesis H_{ 1 3 }:
Stage 1 Stage 2
Conditional error 0.0000000 0.0510653
Upper boundary 2.2100000 2.1400000
Lower boundary 0.7864987 2.1400000
Intersection hypothesis H_{ 2 3 }:
Stage 1 Stage 2
Conditional error 0.0000000 0.04326494
Upper boundary 2.2100000 1.90000000
Lower boundary 0.7864987 1.90000000
Intersection hypothesis H_{ 1 2 3 }:
Stage 1 Stage 2
Conditional error 0.0000000 0.04112744
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Upper boundary 2.3600000 2.22000000
Lower boundary 0.7864987 2.22000000
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